GENR is a few at 1.29
Genaera Corporation to Present at IBC Ocular Anti-angiogenesis Conference
Monday March 27, 8:00 am ET
PLYMOUTH MEETING, Pa., March 27 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR - News) will present at the IBC Third Annual Ocular Anti- angiogenesis Conference being held March 29-30, 2006 at the Hotel @ MIT in Cambridge, MA. Michael J. Gast, M.D., Ph.D., Senior Vice President, Clinical Research and Development, will present on Wednesday, March 29, 2006 at 3:00 PM.
ADVERTISEMENT
The presentation will highlight recent findings from the Company's Phase II clinical trials with EVIZON(TM) (squalamine lactate) for the treatment of wet age-related macular degeneration (AMD). Squalamine lactate is a first-in- class, anti-angiogenic small molecule being developed for exudative AMD and oncology.
Genaera Corporation is a biopharmaceutical company committed to developing medicines to address substantial unmet medical needs in major pharmaceutical markets. The Company has four products in development for the treatment of eye, cancer and respiratory disorders. EVIZON(TM) (squalamine lactate) is Genaera's lead product in development for ophthalmic indications, specifically wet age-related macular degeneration (AMD). Genaera's other programs include: squalamine for the treatment of cancer; interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma; and LOMUCIN(TM), a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of chronic respiratory disease.
